ND-2110

• UNSPSC Description:

  ND-2110 is a selective IRAK4 inhibitor (Ki: 7.5 nM). ND-2110 binds to the ATP pocket of IRAK4. ND-2110 targets the subset of activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL) cell lines with MYD88 L265P mutations,. ND-2110 inhibits LPS-induced TNF production, alleviates collagen-induced arthritis, and blocks gout formation in mouse models[1].

• Target Antigen:

  IRAK

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/nd-2110.html

• Smiles:

  O=C(N)C[C@H]1CCC2=C1C3=C(O[C@@H]4CC[C@@H](N5CCOCC5)CC4)N=CN=C3S2

• Molecular Weight:

  416.54

• References & Citations:

  [1]Kelly PN, et al. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J Exp Med. 2015 Dec 14;212(13):2189-201.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1388894-17-4